Drug updated on 3/28/2024
| Dosage Form | Tablet (oral; 10 mg, 30 mg, 60 mg) |
| Drug Class | Calcitonin gene-related peptide receptor antagonists |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the preventive treatment of migraine in adults.
Summary
- Atogepant (Qulipta) is a potent, selective, orally available antagonist of the calcitonin gene-related peptide (CGRP) receptor that has been approved for the preventive treatment of migraine in adults.
- According to six systematic reviews/meta-analyses documents reviewed, atogepant was found to be more effective than placebo in reducing monthly migraine days and acute medication use days across different doses ranging from 10mg to 60mg daily.
- The patient population primarily consisted of adult patients diagnosed with episodic or chronic migraines; about 87.7% were women with an average age around 41 years old.
- Compared to other CGRP antagonists such as erenumab, fremanezumab, eptinezumab and galcanezumab used for migraine prevention, atogepant showed comparable efficacy but had fewer side effects making it a potentially preferable choice especially for individuals who do not wish to take injections or require prolonged duration drug effect.
- Adverse events reported during trials included nausea and constipation which were more commonly observed among patients treated with higher doses of atogepant (30-60 mg/day). However overall there was no significant difference between adverse event rates associated with atogepant compared to placebo groups indicating its safety profile is favorable.
- Despite promising results from these studies further research including head-to-head trials comparing Qulipta against other CGRP antagonists are required before definitive conclusions can be drawn regarding its place in clinical practice for preventing migraines amongst adults according their specific needs and preferences based on individual health profiles and lifestyle considerations like route administration preference etc.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Qulipta (atogepant) Prescribing Information. | 2023 | AbbVie Inc., North Chicago, IL |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Comparative efficacy and safety of five anti-calcitonin gene-related peptide agents for migraine prevention. | 2023 | The Clinical Journal of Pain |
| Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials. | 2022 | Cephalalgia |
| Atogepant for the prevention of episodic migraine in adults: a systematic review and meta-analysis of efficacy and safety. | 2022 | Neurology and Therapy |
| Atogepant for migraine prevention: a systematic review of efficacy and safety. | 2022 | Clinical Drug Investigation |
| The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials. | 2022 | The Journal of Headache and Pain |
| Atogepant for migraine prevention: a systematic review of efficacy and safety. | 2022 | Clinical Drug Investigation |